GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

by barry-jtcir | Apr 16, 2024 | Press Releases

Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation Continued advancement of an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune...

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

by barry-jtcir | Apr 8, 2024 | Press Releases

LA JOLLA, CA, April 08, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

by barry-jtcir | Apr 1, 2024 | Press Releases

Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024 GRI-0803 systemic lupus erythematosus (SLE) program advancing towards...

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

by barry-jtcir | Mar 28, 2024 | Press Releases

Live webcast on Wednesday, April 3rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

by barry-jtcir | Mar 14, 2024 | Press Releases

Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation LA...

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

by barry-jtcir | Mar 4, 2024 | Press Releases

MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and topline data H2 2024 UK enrollment to be supported by...